About Xtant Medical (NYSEAMERICAN:XTNT)
Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. It also processes and distributes sports allografts, milled spinal allografts and allografts for multi-disciplinary applications.
Industry, Sector and Symbol
Industry Advanced Medical Equipment & Technology
Trailing P/E Ratio-0.308201732042792
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on Assets-25.99%
Xtant Medical (NYSEAMERICAN:XTNT) Frequently Asked Questions
What is Xtant Medical's stock symbol?
Xtant Medical trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XTNT."
When did Xtant Medical's stock split? How did Xtant Medical's stock split work?
Xtant Medical's stock reverse split on the morning of Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Xtant Medical stock prior to the reverse split would have 8 shares after the split.
How were Xtant Medical's earnings last quarter?
Xtant Medical Holdings Inc (NYSEAMERICAN:XTNT) posted its quarterly earnings results on Tuesday, May, 9th. The medical device company reported ($3.46) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($3.54) by $0.08. The medical device company earned $22.08 million during the quarter. View Xtant Medical's Earnings History.
Where is Xtant Medical's stock going? Where will Xtant Medical's stock price be in 2018?
1 brokerages have issued 1-year target prices for Xtant Medical's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Xtant Medical's stock price to reach $10.00 in the next year. View Analyst Ratings for Xtant Medical.
Are investors shorting Xtant Medical?
Xtant Medical saw a decrease in short interest in January. As of January 31st, there was short interest totalling 782,950 shares, a decrease of 9.6% from the January 12th total of 866,321 shares. Based on an average daily trading volume, of 193,317 shares, the days-to-cover ratio is presently 4.1 days. Approximately 5.9% of the shares of the stock are short sold.
Who are some of Xtant Medical's key competitors?
Some companies that are related to Xtant Medical include GenMark Diagnostics (GNMK), Cytosorbents (CTSO), Cogentix Medical (CGNT), Corindus Vascular Robotics (CVRS), Harvard Bioscience (HBIO), Alliance HealthCare Services (AIQ), Viveve Medical (VIVE), Fulgent Genetics (FLGT), IRIDEX (IRIX), Edap Tms (EDAP), Luna Innovations (LUNA), Presbia (LENS), Advanced Oncotherapy (AVO), Electromed (ELMD), Digirad (DRAD), BIOLASE (BIOL), Reshape Lifesciences (RSLS) and Dynatronics (DYNT).
Who are Xtant Medical's key executives?
Xtant Medical's management team includes the folowing people:
- Carl D. O'Connell, President, Chief Executive Officer (Age 53)
- Darrel Lee Holmes, Chief Operating Officer (Age 62)
- Gregory Juda Ph.D., Chief Scientific Officer (Age 39)
- John K. Bakewell, Director (Age 55)
- Michael Eggenberg, Director
- Michael R. Mainelli Jr., Director (Age 55)
- Robert E. McNamara, Director (Age 61)
- Jeffrey J. Peters, Director
Who owns Xtant Medical stock?
Who sold Xtant Medical stock? Who is selling Xtant Medical stock?
Who bought Xtant Medical stock? Who is buying Xtant Medical stock?
How do I buy Xtant Medical stock?
Shares of Xtant Medical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xtant Medical's stock price today?
One share of Xtant Medical stock can currently be purchased for approximately $5.88.
How big of a company is Xtant Medical?
Xtant Medical has a market capitalization of $149.32 million.
How can I contact Xtant Medical?
Xtant Medical's mailing address is 664 Cruiser Ln, BELGRADE, MT 59714-9719, United States. The medical device company can be reached via phone at +1-406-3880480.
MarketBeat Community Rating for Xtant Medical (XTNT)MarketBeat's community ratings are surveys of what our community members think about Xtant Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Xtant Medical (NYSEAMERICAN:XTNT) Earnings History and Estimates Chart
Xtant Medical (NYSEAMERICAN XTNT) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/21/2017||Q3 2017||($5.64)||$19.79 million||View||N/A|
|8/9/2017||Q2 2017||($6.48)||$21.41 million||View||N/A|
|5/9/2017||Q1 2017||($3.54)||($3.46)||$22.08 million||View||Listen|
|3/9/2017||Q4 2016||($3.60)||($3.68)||$24.45 million||$24.47 million||View||Listen|
|11/7/2016||Q3 2016||($3.84)||($4.80)||$22.80 million||$23.09 million||View||N/A|
|8/1/2016||Q2 2016||($4.80)||($4.44)||$22.25 million||$21.46 million||View||N/A|
|5/4/2016||Q1||($4.68)||($5.28)||$21.94 million||$20.98 million||View||N/A|
|3/15/2016||Q415||($2.64)||$11.64||$23.34 million||$22.30 million||View||N/A|
|11/11/2015||Q3||($1.80)||($7.68)||$19.64 million||$17.69 million||View||Listen|
|8/12/2015||($3.48)||($4.92)||$10.15 million||$9.89 million||View||N/A|
|5/5/2015||Q1 2015||($3.36)||($6.60)||$9.60 million||$9.50 million||View||N/A|
|3/17/2015||Q414||($4.20)||($5.52)||$8.90 million||$9.10 million||View||N/A|
|8/12/2014||Q214||($5.64)||($4.20)||$8.85 million||$5.60 million||View||N/A|
|5/6/2014||Q114||($0.48)||($0.96)||$9.73 million||$8.90 million||View||N/A|
|3/19/2014||Q413||($0.84)||($0.96)||$8.00 million||$8.30 million||View||N/A|
|11/7/2013||Q3 2013||($4.80)||($9.60)||$8.91 million||$7.93 million||View||N/A|
|8/6/2013||Q2 2013||($4.80)||($7.20)||$9.25 million||$8.27 million||View||N/A|
|5/9/2013||Q1 2013||($0.72)||($0.48)||$10.08 million||$8.62 million||View||N/A|
|11/7/2012||Q312||($0.48)||($0.72)||$9.29 million||$8.90 million||View||N/A|
Xtant Medical (NYSEAMERICAN:XTNT) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Xtant Medical (NYSEAMERICAN:XTNT)
No dividend announcements for this company have been tracked by MarketBeat.com
Xtant Medical (NYSEAMERICAN XTNT) Insider Trading and Institutional Ownership History
Xtant Medical (NYSEAMERICAN XTNT) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/9/2016||Daniel S Goldberger||CEO||Buy||5,000||$2.34||$11,700.00||15,510|| |
|12/3/2015||Kent L. Swanson||Director||Buy||3,300||$2.83||$9,339.00||83,128|| |
|11/20/2015||David Louis Kirschman||EVP||Buy||2,000||$2.99||$5,980.00||1,701,063|| |
|11/20/2015||Kent L. Swanson||Director||Buy||5,000||$3.00||$15,000.00||79,828|| |
|11/19/2015||David Louis Kirschman||EVP||Buy||2,000||$2.90||$5,800.00||1,699,063|| |
|11/16/2015||Daniel S Goldberger||CEO||Buy||3,000||$2.80||$8,400.00||15,510|| |
|9/4/2015||Daniel S Goldberger||CEO||Buy||81,522||$3.68||$300,000.96||12,510|| |
|9/4/2015||Jon M Wickwire||Director||Buy||10,869||$3.68||$39,997.92||31,247|| |
|5/22/2014||Daniel S Goldberger||CEO||Buy||25,000||$0.65||$16,250.00|| |
|5/20/2014||Gregory Alexander Juda||Insider||Buy||20,000||$0.69||$13,800.00|| |
|5/7/2014||Guy S Cook||Major Shareholder||Sell||1,365,000||$0.66||$900,900.00|| |
|5/6/2014||Guy S Cook||Major Shareholder||Sell||885,000||$0.75||$663,750.00|| |
|5/2/2014||Guy S Cook||Major Shareholder||Sell||280,000||$0.73||$204,400.00|| |
|4/30/2014||Guy S Cook||Major Shareholder||Sell||85,000||$0.70||$59,500.00|| |
|4/25/2014||Guy S Cook||Major Shareholder||Sell||100,000||$0.70||$70,000.00|| |
|4/24/2014||Guy S Cook||Major Shareholder||Sell||390,000||$0.70||$273,000.00|| |
|4/22/2014||Guy S Cook||Major Shareholder||Sell||410,000||$0.71||$291,100.00|| |
|4/17/2014||Guy S Cook||Major Shareholder||Sell||75,000||$0.70||$52,500.00|| |
|4/9/2014||Guy S Cook||Major Shareholder||Sell||410,000||$0.72||$295,200.00|| |
|1/15/2014||Guy S Cook||Major Shareholder||Buy||160,000||$0.64||$102,400.00|| |
|1/7/2014||Guy S Cook||Major Shareholder||Sell||273,300||$0.53||$144,849.00|| |
|12/26/2013||Guy S Cook||Major Shareholder||Sell||64,380||$0.53||$34,121.40|| |
|12/24/2013||Guy S Cook||Major Shareholder||Sell||300,000||$0.44||$132,000.00|| |
|12/11/2013||Guy S Cook||Major Shareholder||Sell||160,000||$0.42||$67,200.00|| |
|11/19/2013||Gregory Alexander Juda||Insider||Buy||20,000||$0.45||$9,000.00|| |
|11/12/2013||Daniel S Goldberger||CEO||Buy||50,000||$0.48||$24,000.00|| |
|9/20/2013||Guy S Cook||Major Shareholder||Sell||30,000||$0.60||$18,000.00|| |
|9/13/2013||Darrel Lee Holmes||COO||Sell||30,000||$0.57||$17,100.00|| |
|8/28/2013||Guy S Cook||Major Shareholder||Sell||400,000||$0.56||$224,000.00|| |
|8/26/2013||Daniel S Goldberger||CEO||Buy||20,000||$0.60||$12,000.00|| |
|8/19/2013||Daniel S Goldberger||CEO||Buy||16,194||$0.59||$9,554.46|| |
|8/16/2013||Daniel S Goldberger||CEO||Buy||13,806||$0.58||$8,007.48|| |
|6/18/2013||Guy S Cook||Major Shareholder||Sell||372,859||$0.52||$193,886.68|| |
|6/13/2013||Guy S Cook||Major Shareholder||Sell||175,000||$0.55||$96,250.00|| |
|6/13/2013||Kent L Swanson||Director||Buy||100,000||$0.55||$55,000.00|| |
|6/12/2013||Guy S Cook||Major Shareholder||Sell||2,600||$0.55||$1,430.00|| |
|6/11/2013||Guy S Cook||Major Shareholder||Sell||21,000||$0.56||$11,760.00|| |
|6/10/2013||Guy S Cook||Major Shareholder||Sell||13,400||$0.56||$7,504.00|| |
|6/7/2013||Guy S Cook||Major Shareholder||Sell||88,000||$0.56||$49,280.00|| |
|9/11/2012||Guy S Cook||CEO||Buy||5,000||$1.71||$8,550.00|| |
Xtant Medical (NYSEAMERICAN XTNT) News Headlines
Xtant Medical (NYSEAMERICAN:XTNT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Xtant Medical (NYSEAMERICAN:XTNT) Income Statement, Balance Sheet and Cash Flow Statement
Xtant Medical (NYSEAMERICAN XTNT) Stock Chart for Friday, February, 23, 2018